← Leaderboards
Patricia Pavlinac
University Of Washington
$6,692,400
Attributed
$6,692,400
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,692,400 · 2
By mechanism
R01$6,692,400 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Judd L. Walson$5,514,597
- Gwendolyn Wood$1,931,162
- Sheila A. Lukehart$22,581,544
- Bonnie W Ramsey$21,623,756
- Lisa E Manhart$10,223,947
Others in their field
Other Emerging Leaders on “Growth”
- Prasant Mohapatra · University Of California At Davis$41,945,816
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$21,828,548
- Abraham Aizer Brody · New York University School Of Medicine$16,015,961
- Jeffrey Reich · Sparian Biosciences, Inc.$13,729,307
- Gary Fanger · Rise Therapeutics, Llc$13,256,050
- Maurizio Macaluso · Cincinnati Childrens Hosp Med Ctr$12,355,450
Research focus
GrowthRandomizedEnterobacteriaceaeFunctional DisorderMortality RiskPreventEnteralEnteric PathogenFailureAntimicrobialHospitalizationKenyaNutritionalPrevalenceDeteriorationDouble-Blind MethodAntibiotic ResistanceCampylobacterAntibioticsCessation Of LifeChildChildhoodHigh RiskRecovery
Grant awards (11)
Lactoferrin and lysozyme to promote nutritional, clinical, and enteric recovery: A factorial placebo-controlled randomized trial among children with diarrhea and malnutrition$642,554
R01 · FY2025 · HD · contact PI
The role of enteric pathogens and antimicrobial resistance in driving clinical and nutritional deterioration, and azithromycin's potential effect, among children discharged from hospital in Kenya$703,337
R01 · FY2024 · AI · contact PI
Lactoferrin and lysozyme to promote nutritional, clinical, and enteric recovery: A factorial placebo-controlled randomized trial among children with diarrhea and malnutrition$613,886
R01 · FY2024 · HD · contact PI
The role of enteric pathogens and antimicrobial resistance in driving clinical and nutritional deterioration, and azithromycin's potential effect, among children discharged from hospital in Kenya$675,966
R01 · FY2023 · AI · contact PI
Lactoferrin and lysozyme to promote nutritional, clinical, and enteric recovery: A factorial placebo-controlled randomized trial among children with diarrhea and malnutrition$551,936
R01 · FY2023 · HD · contact PI
The role of enteric pathogens and antimicrobial resistance in driving clinical and nutritional deterioration, and azithromycin's potential effect, among children discharged from hospital in Kenya$79,253
R01 · FY2023 · AI · contact PI
The role of enteric pathogens and antimicrobial resistance in driving clinical and nutritional deterioration, and azithromycin's potential effect, among children discharged from hospital in Kenya$677,721
R01 · FY2022 · AI · contact PI
Lactoferrin and lysozyme to promote nutritional, clinical, and enteric recovery: A factorial placebo-controlled randomized trial among children with diarrhea and malnutrition$553,912
R01 · FY2022 · HD · contact PI
The role of enteric pathogens and antimicrobial resistance in driving clinical and nutritional deterioration, and azithromycin's potential effect, among children discharged from hospital in Kenya$740,701
R01 · FY2021 · AI · contact PI
Lactoferrin and lysozyme to promote nutritional, clinical, and enteric recovery: A factorial placebo-controlled randomized trial among children with diarrhea and malnutrition$670,887
R01 · FY2021 · HD · contact PI
The role of enteric pathogens and antimicrobial resistance in driving clinical and nutritional deterioration, and azithromycin's potential effect, among children discharged from hospital in Kenya$782,247
R01 · FY2020 · AI · contact PI